Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study

Reineke A. Schoot; Pieter Taselaar; Giovanni Scarzello; Frederic Kolb; Beatrice Coppadoro; Simone ter Horst; Henry Mandeville; Andrea Ferrari; Raquel Hladun; Sylvie Helfre; Sima Ferman; Anna Kelsey; Marinka L.F. Hol; Christine Devalck; Myriam Ben-Arush; Daniel Orbach; Julia Chisholm; Meriel Jenney; Veronique Minard-Colin; Gianni Bisogno; Johannes H.M. Merks

doi:10.1002/hed.27994

Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study

Reineke A. Schoot^*
, Pieter Taselaar
, Giovanni Scarzello
, Frederic Kolb
, Beatrice Coppadoro
, Simone ter Horst
, Henry Mandeville
, Andrea Ferrari
, Raquel Hladun
, Sylvie Helfre
, Sima Ferman
, Anna Kelsey
, Marinka L.F. Hol
, Christine Devalck
, Myriam Ben-Arush
, Daniel Orbach
, Julia Chisholm
, Meriel Jenney
, Veronique Minard-Colin
, Gianni Bisogno

Johannes H.M. Merks

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Downloads (Pure)

Abstract

Background: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. Methods: Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. Results: Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%–65%), 5-year overall survival was 65% (95% CI 60%–70%). Conclusions: The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. Trial Registration: EudraCT number 2005-000217-35.

Original language	English
Pages (from-to)	974-982
Number of pages	9
Journal	Head and Neck
Volume	47
Issue number	3
Early online date	15 Nov 2024
DOIs	https://doi.org/10.1002/hed.27994
Publication status	Published - Mar 2025

Keywords

head and neck
parameningeal
pediatric
prognostic risk factors
rhabdomyosarcoma

Access to Document

10.1002/hed.27994Licence: CC BY-NC-ND

Head Neck - 2024 - Schoot - Parameningeal Rhabdomyosarcoma Results of the European Pediatric Soft Tissue Sarcoma StudyFinal published version, 328 KBLicence: CC BY-NC-ND

Cite this

Schoot, R. A., Taselaar, P., Scarzello, G., Kolb, F., Coppadoro, B., Horst, S. T., Mandeville, H., Ferrari, A., Hladun, R., Helfre, S., Ferman, S., Kelsey, A., Hol, M. L. F., Devalck, C., Ben-Arush, M., Orbach, D., Chisholm, J., Jenney, M., Minard-Colin, V., ... Merks, J. H. M. (2025). Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study. Head and Neck, 47(3), 974-982. https://doi.org/10.1002/hed.27994

@article{194881893af4495682ad07ba54aa7408,

title = "Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study",

abstract = "Background: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. Methods: Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. Results: Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60\% (95\% confidence interval (CI) 55\%–65\%), 5-year overall survival was 65\% (95\% CI 60\%–70\%). Conclusions: The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94\% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. Trial Registration: EudraCT number 2005-000217-35.",

keywords = "head and neck, parameningeal, pediatric, prognostic risk factors, rhabdomyosarcoma",

author = "Schoot, \{Reineke A.\} and Pieter Taselaar and Giovanni Scarzello and Frederic Kolb and Beatrice Coppadoro and Horst, \{Simone ter\} and Henry Mandeville and Andrea Ferrari and Raquel Hladun and Sylvie Helfre and Sima Ferman and Anna Kelsey and Hol, \{Marinka L.F.\} and Christine Devalck and Myriam Ben-Arush and Daniel Orbach and Julia Chisholm and Meriel Jenney and Veronique Minard-Colin and Gianni Bisogno and Merks, \{Johannes H.M.\}",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Head \& Neck published by Wiley Periodicals LLC.",

year = "2025",

month = mar,

doi = "10.1002/hed.27994",

language = "English",

volume = "47",

pages = "974--982",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "John Wiley \& Sons Inc.",

number = "3",

}

Schoot, RA, Taselaar, P, Scarzello, G, Kolb, F, Coppadoro, B, Horst, ST, Mandeville, H, Ferrari, A, Hladun, R, Helfre, S, Ferman, S, Kelsey, A, Hol, MLF, Devalck, C, Ben-Arush, M, Orbach, D, Chisholm, J, Jenney, M, Minard-Colin, V, Bisogno, G & Merks, JHM 2025, 'Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study', Head and Neck, vol. 47, no. 3, pp. 974-982. https://doi.org/10.1002/hed.27994

TY - JOUR

T1 - Parameningeal Rhabdomyosarcoma

T2 - Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study

AU - Schoot, Reineke A.

AU - Taselaar, Pieter

AU - Scarzello, Giovanni

AU - Kolb, Frederic

AU - Coppadoro, Beatrice

AU - Horst, Simone ter

AU - Mandeville, Henry

AU - Ferrari, Andrea

AU - Hladun, Raquel

AU - Helfre, Sylvie

AU - Ferman, Sima

AU - Kelsey, Anna

AU - Hol, Marinka L.F.

AU - Devalck, Christine

AU - Ben-Arush, Myriam

AU - Orbach, Daniel

AU - Chisholm, Julia

AU - Jenney, Meriel

AU - Minard-Colin, Veronique

AU - Bisogno, Gianni

AU - Merks, Johannes H.M.

PY - 2025/3

Y1 - 2025/3

N2 - Background: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. Methods: Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. Results: Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%–65%), 5-year overall survival was 65% (95% CI 60%–70%). Conclusions: The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. Trial Registration: EudraCT number 2005-000217-35.

AB - Background: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors. We scored PM site by originating site and by highest risk extension. Methods: Patients with PM RMS were treated within the European pediatric Soft tissue sarcoma Study Group (EpSSG) RMS 2005 study with risk-adapted, multi-modal treatment. Results: Three-hundred-eighty-one patients with PM RMS were included. Radiotherapy was administered in 359 patients (77 with surgery). After a median follow-up of 75 months, 5-year event-free survival was 60% (95% confidence interval (CI) 55%–65%), 5-year overall survival was 65% (95% CI 60%–70%). Conclusions: The outcome for patients with PM RMS has not improved in comparison to previous historical studies, despite the more rigorous application of radiotherapy (94% of patients). Signs of meningeal involvement, PM site, and age at diagnosis remained prognostic risk factors. Trial Registration: EudraCT number 2005-000217-35.

KW - head and neck

KW - parameningeal

KW - pediatric

KW - prognostic risk factors

KW - rhabdomyosarcoma

UR - https://www.scopus.com/pages/publications/85209217617

U2 - 10.1002/hed.27994

DO - 10.1002/hed.27994

M3 - Article

C2 - 39545397

AN - SCOPUS:85209217617

SN - 1043-3074

VL - 47

SP - 974

EP - 982

JO - Head and Neck

JF - Head and Neck

IS - 3

ER -

Parameningeal Rhabdomyosarcoma: Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this